Suppr超能文献

阿米卡星的支气管分泌物水平。

Bronchial secretion levels of amikacin.

作者信息

Dull W L, Alexander M R, Kasik J E

出版信息

Antimicrob Agents Chemother. 1979 Dec;16(6):767-71. doi: 10.1128/AAC.16.6.767.

Abstract

Amikacin was given to 14 noninfected men as three consecutive intramuscular injections (7.5 mg/kg) at 12-h intervals. Serum and bronchial secretion specimens were obtained at various times during flexible fiberoptic bronchoscopy after the final dose. Serum and bronchial secretion concentrations obtained between 1.5 and 2.0 h after the final dose ranged from 17 to 40 mug/ml and 2.3 to 8.4 mug/ml with a mean of 23.7 +/- 2.9 and 5.23 +/- 1.5 mug/ml, +/-1 standard error of the mean, respectively. The highest bronchial secretion concentration in each subject correlated with the highest serum concentration (r = 0.83, P < 0.001), and all concurrent serum and bronchial secretion concentrations demonstrated a significant correlation (r = 0.82, P < 0.001). Clearance occurred at the same rate (half-life serum = 2.84 h; half-life of bronchial secretion = 2.60 h, P > 0.5). The mean bronchial secretion concentration of the 15 specimens obtained more than 7 h after the final dose was less than 1.0 mug/ml, with a range from 0.3 to 1.6 mug/ml. It is concluded that amikacin may achieve minimal inhibitory concentrations for many gram-negative bacteria in the bronchial secretions of noninfected patients 1 to 2 h after the final dose. However, levels fall below the reported minimal inhibitory concentrations against negative bacteria 6 to 7 h after the final dose. Furthermore, bronchial secretion levels may never reach the minimal inhibitory concentration against Pseudomonas aeruginosa.

摘要

对14名未受感染的男性连续3次肌内注射阿米卡星(7.5毫克/千克),间隔12小时。在最后一剂后的不同时间,通过可弯曲纤维支气管镜检查获取血清和支气管分泌物标本。最后一剂后1.5至2.0小时测得的血清和支气管分泌物浓度范围分别为17至40微克/毫升和2.3至8.4微克/毫升,平均值分别为23.7±2.9和5.23±1.5微克/毫升(±1平均标准误差)。每个受试者的最高支气管分泌物浓度与最高血清浓度相关(r = 0.83,P < 0.001),所有同时测得的血清和支气管分泌物浓度均显示出显著相关性(r = 0.82,P < 0.001)。清除率相同(血清半衰期 = 2.84小时;支气管分泌物半衰期 = 2.60小时,P > 0.5)。最后一剂后7小时以上获取的15份标本的平均支气管分泌物浓度低于1.0微克/毫升,范围为0.3至1.6微克/毫升。结论是,在最后一剂后1至2小时,阿米卡星可能在未受感染患者的支气管分泌物中对许多革兰氏阴性菌达到最低抑菌浓度。然而,在最后一剂后6至7小时,其水平降至低于报道的对阴性菌的最低抑菌浓度。此外,支气管分泌物水平可能永远达不到对铜绿假单胞菌的最低抑菌浓度。

相似文献

1
Bronchial secretion levels of amikacin.阿米卡星的支气管分泌物水平。
Antimicrob Agents Chemother. 1979 Dec;16(6):767-71. doi: 10.1128/AAC.16.6.767.
3
Pharmacokinetics of amikacin in patients with impaired renal function.肾功能受损患者中阿米卡星的药代动力学
J Infect Dis. 1976 Nov;134 SUPPL:S343-8. doi: 10.1093/infdis/135.supplement_2.s343.
5
Clinical pharmacology of amikacin and kanamycin.阿米卡星和卡那霉素的临床药理学
J Infect Dis. 1976 Nov;134 SUPPL:S312-5. doi: 10.1093/infdis/135.supplement_2.s312.
6
Pharmacology of amikacin in humans.阿米卡星在人体中的药理学。
Antimicrob Agents Chemother. 1974 May;5(5):508-12. doi: 10.1128/AAC.5.5.508.
8
Pharmacological evaluation of amikacin in neonates.阿米卡星在新生儿中的药理学评估。
Antimicrob Agents Chemother. 1975 Jul;8(1):86-90. doi: 10.1128/AAC.8.1.86.

引用本文的文献

5
Quantification of amikacin in bronchial epithelial lining fluid in neonates.定量检测新生儿支气管上皮衬液中的阿米卡星。
Antimicrob Agents Chemother. 2011 Sep;55(9):3990-3. doi: 10.1128/AAC.00277-11. Epub 2011 Jun 27.
6
Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.危重症中抗生素的药代动力学和药效学考量
Intensive Care Med. 2004 Dec;30(12):2145-56. doi: 10.1007/s00134-004-2428-9. Epub 2004 Nov 5.
7
Drug monitoring in nonconventional biological fluids and matrices.非常规生物流体和基质中的药物监测。
Clin Pharmacokinet. 1996 Mar;30(3):211-28. doi: 10.2165/00003088-199630030-00003.
10
Penetration of cefotaxime into respiratory secretions.头孢噻肟在呼吸道分泌物中的穿透性。
Antimicrob Agents Chemother. 1987 May;31(5):815-7. doi: 10.1128/AAC.31.5.815.

本文引用的文献

6
10
Amikacin: a rapid and sensitive radioimmunoassay.阿米卡星:一种快速灵敏的放射免疫测定法。
Antimicrob Agents Chemother. 1975 Jan;7(1):42-5. doi: 10.1128/AAC.7.1.42.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验